Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma
Cet article passe en revue les principales données et informations pratiques permettant d'utiliser dans un cadre clinique des lymphocytes CAR-T anti-CD19, en particulier l'axicabtagène ciloleucel et le tisagenlecleucel, pour traiter un lymphome diffus à grandes cellules B récidivant ou réfractaire
Chimeric antigen receptor (CAR) T-cells demonstrate efficacy in B-cell malignancies, leading to FDA approval of axicaptagene ciloleucel in October 2017 and tisagenlecleucel in May 2018 for large B-cell lymphomas after two prior lines of therapy. Durable remissions are seen in 30-40% of study-treated patients, but unique toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews the data to-date within the context of current diffuse large B-cell lymphoma management, focusing on axicaptagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel.
Blood , résumé, 2017